CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $66.3 million in its second quarter.
The Cambridge, Massachusetts-based company said it had a loss of 51 cents per share. Earnings, adjusted for one-time gains and costs, came to 32 cents per share.
The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share.
The RNA interference drug developer posted revenue of $773.7 million in the period, which also beat Street forecasts. Twelve analysts surveyed by Zacks expected $673 million.
Alnylam shares have climbed 44% since the beginning of the year. The stock has increased 45% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
